Syros Pharmaceuticals, Inc. (SYRS) Forecasted to Earn FY2017 Earnings of ($2.10) Per Share
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Equities research analysts at Oppenheimer Holdings boosted their FY2017 earnings per share estimates for shares of Syros Pharmaceuticals in a report released on Wednesday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will earn ($2.10) per share for the year, up from their previous estimate of ($2.13). Oppenheimer Holdings also issued estimates for Syros Pharmaceuticals’ Q4 2017 earnings at ($0.56) EPS, Q1 2018 earnings at ($0.88) EPS, Q2 2018 earnings at ($0.91) EPS, Q3 2018 earnings at ($0.94) EPS, Q4 2018 earnings at ($0.97) EPS, FY2018 earnings at ($3.69) EPS, FY2019 earnings at ($2.87) EPS and FY2020 earnings at ($0.88) EPS.
A number of other brokerages have also recently commented on SYRS. JMP Securities cut Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Wedbush restated an “outperform” rating and set a $22.84 target price (down from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Cann restated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a report on Monday, August 21st. Finally, Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $26.14.
Syros Pharmaceuticals (NASDAQ SYRS) opened at $11.65 on Monday. Syros Pharmaceuticals has a twelve month low of $10.22 and a twelve month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53).
A number of hedge funds have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. raised its position in Syros Pharmaceuticals by 95.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock valued at $614,000 after purchasing an additional 20,409 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Syros Pharmaceuticals in the 3rd quarter valued at about $975,000. Trexquant Investment LP acquired a new stake in Syros Pharmaceuticals in the 3rd quarter valued at about $282,000. JPMorgan Chase & Co. raised its position in Syros Pharmaceuticals by 15.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after purchasing an additional 17,330 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Syros Pharmaceuticals in the 3rd quarter valued at about $133,000. 54.15% of the stock is currently owned by institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.